PFE Dec 2025 25.000 call
| Previous close | 5.3000 |
| Open | 5.3400 |
| Bid | 3.9500 |
| Ask | 4.9500 |
| Strike | 25.00 |
| Expiry date | 2025-12-19 |
| Day's range | 4.9500 - 5.3400 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.11k |
- Reuters
UPDATE 2-Pfizer reports patient death in Duchenne gene therapy study
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial is testing boys 2 to three years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
- Reuters
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial tested boys 2 years to less than 4 years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
Insider Monkey15 Best S&P 500 Dividend Stocks To Buy Now
In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]
